title: An in vitro model for disease-specific immunotherapy in myasthenia gravis using soluble MHC class II bound to AChR-derived peptide.
authors.affiliation: Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, United Kingdom.
authors.forename: M W
authors.initials: MW
authors.lastname: Nicolle
authors.forename: A
authors.initials: A
authors.lastname: Vincent
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: B
authors.initials: B
authors.lastname: Nag
authors.forename: N
authors.initials: N
authors.lastname: Willcox
authors.forename: J
authors.initials: J
authors.lastname: Newsom-Davis
mesh_terms: D006684:HLA-DR Antigens / Q000737:chemistry*; D007167:Immunotherapy; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D009157:Myasthenia Gravis / Q000628:therapy*; D011978:Receptors, Nicotinic / Q000737:chemistry* / Q000276:immunology; D012995:Solubility; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
chemical_list: D006684:HLA-DR Antigens; D011978:Receptors, Nicotinic